LFST — LifeStance Health Group, Inc. stock price, charts and financials
QT78LifeStance Health Group, Inc.LifeStance Health Group, Inc. (NASDAQ: LFST) is a Healthcare company in the Medical - Care Facilities industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 174.09 | EPS (ttm) | 0.06 | Insider Own | - | Shs Outstand | 387.83M | Perf Week | -3.85% |
| Market Cap | 4.06B | Forward P/E | 51.63 | EPS next Y | 0.20 | Insider Trans | -10.29% | Shs Float | 203.03M | Perf Month | -8.31% |
| Enterprise Value | 4.07B | PEG | 0.11 | EPS next Q | - | Inst Own | - | Short Float | 4.66% | Perf Quarter | 38.44% |
| Income | 23.17M | P/S | 2.72 | EPS this Y | 126.78% | Inst Trans | - | Short Ratio | 2.02 | Perf Half Y | 48.23% |
| Sales | 1.49B | P/B | 2.75 | EPS next Y | 49.17% | ROA | 1.08% | Short Interest | 9.46M | Perf YTD | 48.86% |
| Book/sh | - | P/C | 22.26 | EPS next 5Y | 68.15% | ROE | 1.56% | 52W High | 11.83 -10.88% | Perf Year | 147.75% |
| Cash/sh | - | P/FCF | 22.74 | EPS past 3/5Y | - | ROIC | 1.58% | 52W Low | 3.76 180.21% | Perf 3Y | 13.17% |
| Dividend Est. | - | EV/EBITDA | 41.37 | Sales past 3/5Y | 18.31% 30.45% | Gross Margin | 32.60% | Volatility | 3.56% 3.54% | Perf 5Y | -53.36% |
| Dividend TTM | - | EV/Sales | 2.72 | EPS Y/Y TTM | 140.00% | Oper. Margin | 3.00% | ATR (14) | 0.40 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.48 | Sales Y/Y TTM | 19.42% | Profit Margin | 1.55% | RSI (14) | 49.09 | Recom | 2.18 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.48 | EPS Q/Q | - | SMA20 | -4.34% | Beta | 1.11 | Target Price | 12.17 |
| Payout | 0.00% | Debt/Eq | 0.13 | Sales Q/Q | 21.02% | SMA50 | 9.72% | Rel Volume | 0.61 | Prev Close | 10.48 |
| Employees | 8,349 | LT Debt/Eq | 0.10 | Earnings | Aug 06 | SMA200 | 41.33% | Avg Volume | 4.16M | Price | 10.54 |
| IPO Date | Jun 10, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 457.18% 4.14% | Net Debt/EBITDA | 0.01 | Volume | 2,524,902 | Change | 0.57% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-24-26 | Reiterated | BTIG | Buy | $11 → $15 |
| Jul-21-26 | Reiterated | Canaccord Genuity | Buy | $11 → $13 |
| Jul-14-26 | Reiterated | Barclays | Overweight | $8.00 → $13 |
| Jul-13-26 | Reiterated | Keybanc | Overweight | $8.50 → $13 |
| Jun-05-26 | Downgrade | Goldman Sachs | Buy → Neutral | $9.00 |
| May-08-26 | Reiterated | Canaccord Genuity | Buy | $10 → $11 |
| Feb-25-26 | Reiterated | BMO Capital | $8.00 → $10 | |
| Feb-02-26 | Reiterated | BTIG | Buy | $10 → $11 |
| Jan-08-26 | Reiterated | KeyBanc | $6.50 → $8.50 | |
| Jan-08-26 | Reiterated | Canaccord Genuity | $8.00 → $9.00 |
LifeStance Health Group, Inc. specializes in delivering outpatient mental healthcare services through its subsidiary network. The company offers a comprehensive array of mental health solutions, encompassing psychiatric evaluations and treatment, specialized psychological and neuropsychological testing, and diverse therapeutic modalities including individual, family, and group therapy sessions. The organization addresses a wide spectrum of mental health conditions, ranging from common issues like anxiety and depression to more complex challenges such as bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder. Patients have access to care through various channels: virtually via its online platform or in-person at its many centers located throughout 32 states. LifeStance is dedicated to supporting individuals across all age groups, providing care for children, adolescents, adults, and the elderly. LifeStance Health Group, Inc. was founded in 2017 and its main offices are situated in Scottsdale, Arizona.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,494 | 1,424 | 1,251 | 1,056 | 860 | 668 | 377 | 213 | |
| Cost of Goods Sold Incl. D&A | 1,008 | 963 | 849 | 754 | 623 | 466 | 243 | 150 | |
| Gross Profit | 487 | 461 | 402 | 302 | 237 | 202 | 134 | 62 | |
| Selling, General and Administrative Excl. Other | 388 | 382 | 363 | 411 | 378 | 434 | 88 | 41 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | 54 | 55 | 71 | 80 | 69 | 54 | 31 | 6 | |
| Operating Income | 44 | 24 | -32 | -189 | -210 | -286 | 15 | 15 | |
| Interest Expense | 11 | 12 | 27 | 21 | 20 | 39 | 22 | 5 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -1 | 0 | 1 | 4 | -3 | -8 | -38 | -2 | |
| Net Income Before Taxes | 34 | 12 | -58 | -207 | -233 | -333 | -44 | 8 | |
| Income Taxes | 11 | 3 | 0 | -20 | -17 | -26 | -6 | 2 | |
| Consolidated Net Income | 23 | 10 | -57 | -186 | -216 | -307 | -38 | 6 | |
| Net Income From Continuing Operations | 23 | 10 | -57 | -186 | -216 | -307 | -38 | 6 | |
| Net Income | 23 | 10 | -57 | -186 | -216 | -307 | -38 | 6 | |
| EPS (Recurring) | 0.06 | 0.03 | -0.15 | -0.51 | -0.61 | -1.05 | -0.83 | -0.16 | |
| EPS (Basic, Before Extraordinaries) | 0.06 | 0.03 | -0.15 | -0.51 | -0.61 | -1.05 | -0.83 | -0.16 | |
| EPS (Diluted) | 0.06 | 0.02 | -0.15 | -0.51 | -0.61 | -1.05 | -0.83 | -0.16 | |
| EBITDA | 99 | 79 | 40 | -105 | -144 | -240 | 9 | 19 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 175.67 | 352.00 | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.73 | 1.91 | 2.23 | 2.72 | 2.04 | 4.67 | — | — | |
| Gross Margin | 32.60 | 32.37 | 32.13 | 28.60 | 27.56 | 30.24 | 35.54 | 29.11 | |
| Operating Margin | 2.95 | 1.69 | -2.56 | -17.90 | -24.42 | -42.81 | 3.98 | 7.04 | |
| Net Margin | 1.54 | 0.70 | -4.56 | -17.61 | -25.12 | -45.96 | -10.08 | 2.82 | |
| Shares Outstanding | 387 | 386 | 379 | 367 | 355 | 328 | 374 | 374 | |
| Market Capitalization | 4,079 | 2,717 | 2,793 | 2,874 | 1,754 | 3,123 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Bessler Robert | Director | Jun 26 '26 | Sale | 10.13 | 894,337 | 9,059,634 | 539,763 | Jun 30 |
| TPG GP A, LLC | 10% Owner | May 12 '26 | Sale | 8.02 | 28,281,943 | 226,821,183 | 111,744,614 | May 14 |
| Bessler Robert | Director | May 12 '26 | Sale | 8.02 | 575,034 | 4,611,772 | 986,931 | May 14 |
| Shuey Eric | Director | May 12 '26 | Sale | 8.02 | 243,362 | 1,951,763 | 867,562 | May 14 |
| BLACK DARREN M. | Director | May 12 '26 | Sale | 8.02 | 5,899,661 | 47,315,281 | 23,310,115 | May 14 |
| Bessler Robert | Director | May 07 '26 | Sale | 8.55 | 75,000 | 641,250 | 1,236,948 | May 11 |
| Bessler Robert | Director | Apr 24 '26 | Sale | 7.05 | 62,147 | 438,137 | 1,274,448 | Apr 27 |
| Bessler Robert | Director | Apr 23 '26 | Sale | 7.00 | 7,752 | 54,264 | 1,305,521 | Apr 27 |
| Bessler Robert | Director | Apr 21 '26 | Sale | 7.01 | 5,101 | 35,759 | 1,309,397 | Apr 23 |
| BLACK DARREN M. | Director | Mar 02 '26 | Sale | 7.01 | 4,314,939 | 30,247,722 | 29,209,776 | Mar 04 |
| TPG GP A, LLC | 10% Owner | Mar 02 '26 | Sale | 7.01 | 20,685,061 | 145,002,278 | 140,026,557 | Mar 04 |
| Bessler Robert | Director | Dec 22 '25 | Sale | 7.04 | 1,701 | 11,975 | 1,318,133 | Dec 23 |
| Bessler Robert | Director | Dec 19 '25 | Sale | 7.04 | 119,942 | 844,392 | 1,318,983 | Dec 23 |
| Bessler Robert | Director | Dec 18 '25 | Sale | 7.00 | 6,442 | 45,094 | 1,378,954 | Dec 19 |
| Varanakis Ann | Chief People Officer | Dec 17 '25 | Sale | 6.90 | 50,000 | 345,000 | 315,610 | Dec 19 |